NPS RADAR provides health professionals with timely, independent evidence-based information on new drugs and medical tests and changes to listings on the Pharmaceutical Benefits Scheme.

NPS RADAR is print-published 3 times a year, in line with major updates to the Schedule of Pharmaceutical Benefits, so it is available around the time when new medicines can be prescribed or dispensed.

Our free NPS RADAR email alerts keep subscribers up to date with new drugs and medical tests as each new issue of NPS RADAR is released.

Latest issue

Editorial: Gout: treating an old problem

Trials underpinning approval for a new listing for gout reflect a problem in current management.

Changes to the National Cervical Screening Program

Alternative sampling option, longer interval, increased entry age and a national register among changes to take effect in 2017.

Febuxostat (Adenuric) for chronic symptomatic gout

A new PBS listing for second-line treatment of chronic symptomatic gout associated with hyperuricaemia.

Brief item: PBS listing extended for Apixaban (Eliquis)

From 1 August 2015 the PBS listing for apixaban was extended to include treatment of deep vein throbosis and pulmonary embolism, collectively referred to as venous thromboembolism.

Brief item: Exenatide triple therapy, an option for type 2 diabetes add-on treatment

From 1 October 2015 the PBS listing of exenatide is extended to allow triple therapy in combination with insulin and metformin type 2 diabetes.

Brief item: New supply arrangements for some S100 medicines

From 1 July 2015 prescribing arrangements for PBS S100 medicines for HIV antiretroviral therapy, hepatitis B medicines and clozapine change to reflect that many taking these are managed in the community setting.

Brief item: MBS item number changes for vitamin B12, folate and vitamin D tests

To encourage the quality use of testing under Medicare, vitamin B12 and serum folate are now listed as separate items, and vitamin D testing has been split into two types: testing for deficiency and testing for hypercalcaemia.